Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2015-04-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
重大事项停牌进展公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the suspension of trading (停牌) of the company's stock due to ongoing major matters and negotiations. It mentions the stock code, stock abbreviation, dates of suspension, and regulatory compliance with the Shenzhen Stock Exchange rules. There is no financial data, no detailed report, no voting results, no management changes, or other detailed disclosures. The document is a regulatory announcement about trading suspension, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance-related disclosure.
2015-04-03 Chinese
资产收购项目涉及的江苏顺丰生态园林有限公司苗木资产价值评估说明
Audit Report / Information Classification · 95% confidence The document is an asset valuation report for a biological company's acquisition project, specifically evaluating nursery assets of another company. It includes detailed asset inventory, valuation methods, assumptions, and conclusions with financial figures. The document is 8670 characters long, which is substantial and contains substantive financial and asset evaluation data. It is not a brief announcement or a certification letter but a full asset evaluation report. The content aligns with an Audit Report / Information (AR) category, as it is a standalone asset valuation report related to an acquisition, not a full annual or interim financial report, nor a regulatory filing or announcement. Therefore, the appropriate classification is AR. FY 2014
2015-04-01 Chinese
资产收购项目涉及的江苏阳光生态园科技有限公司部分资产价值评估说明
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report related to an asset acquisition project involving Jiangsu Sihuan Biological Co., Ltd. and Jiangsu Sunshine Ecological Park Technology Co., Ltd. It includes extensive descriptions of asset types (seedlings, buildings, machinery), evaluation methods (market price method, replacement cost method), assumptions, and detailed calculations. The document is technical and focused on asset appraisal rather than financial performance, management changes, or regulatory announcements. It is not an annual or interim financial report, earnings release, or any form of regulatory filing. It is also not a simple announcement or certification but a substantive valuation report. Therefore, the document best fits the category of an Audit Report / Information (AR), as it is a standalone report on asset valuation, which is a form of audit or appraisal information relevant to regulatory or internal review purposes. FY 2014
2015-04-01 Chinese
关于收购资产的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of assets by Jiangsu Sihuan Biological Co., Ltd. It includes extensive information about the transaction, such as the parties involved, asset evaluations, transaction terms, board approvals, and independent director opinions. The document explicitly states that the acquisition has been approved by the board and is pending shareholder approval. It is not a financial report, earnings release, or regulatory certification. Instead, it is a formal announcement of a significant asset acquisition transaction, including details on the transaction structure and approvals. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including asset acquisitions. The document length (over 10,000 characters) and detailed content confirm it is not a mere announcement of a report or a short notice. Therefore, the appropriate classification is CAP with high confidence.
2015-04-01 Chinese
资产收购项目涉及的江苏阳光生态园科技有限公司部分资产价值评估报告
Regulatory Filings
2015-03-27 Chinese
重大事项停牌进展公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the continuation of a trading suspension (stock halt) due to ongoing discussions about a major matter. It references the Shenzhen Stock Exchange rules and the company's application for suspension and extension of suspension. The document does not contain financial data, audit information, or detailed report content. It is a regulatory announcement about trading status related to a significant corporate event, not a full report or financial filing. Given the content and length (544 characters), it fits best as a Regulatory Filing (RNS) rather than a full report or other specific category.
2015-03-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.